X
[{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Therapeutics and Shionogi Announce Expanded Alliance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Therapeutics Becomes a Wholly Owned Subsidiary of Shionogi","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Therapeutics Initiates Phase 2b\/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for BPN14770
Filters
Companies By Therapeutic Area
Details:
BPN14770 (zatolmilast) is an investigational drug that is believed to work by modulating a signaling molecule called cyclic AMP (cAMP), which may promote the maturation of connections between neurons that are impaired in individuals with FXS.
Lead Product(s):
Zatolmilast
Therapeutic Area: Genetic Disease
Product Name: BPN14770
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 27, 2023
Details:
Preclinical animal models show that BPN14770 (zatolmilast) has potential to promote maturation of connections between neurons, which is impaired in patients with FXS, and to protect connections between neurons which otherwise are lost in patients with AD.
Lead Product(s):
Zatolmilast
Therapeutic Area: Genetic Disease
Product Name: BPN14770
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 12, 2022
Details:
In the single-center, randomized, placebo-controlled, two-way crossover study, BPN14770 demonstrated excellent safety as well as benefits on cognitive function and behavior in 30 patients with FXS.
Lead Product(s):
Zatolmilast
Therapeutic Area: Genetic Disease
Product Name: BPN14770
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 02, 2020
Details:
As a result of this acquisition, Shionogi will have all global rights to BPN14770 and all Tetra compounds.
Lead Product(s):
Zatolmilast
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Shionogi
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
May 26, 2020
Details:
This expanded alliance with Shionogi further validates Tetra's platform and the potential for BPN14770 to provide a new treatment option for patients suffering from Alzheimer’s disease.
Lead Product(s):
Zatolmilast
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Shionogi
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
March 06, 2020